SCHEDULE 13G/A: BlackRock Boosts Stake in Gossamer Bio to 6.5%

BlackRock, Inc. has reported a beneficial ownership of 6.5% in Gossamer Bio, Inc. common stock as of December 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G for Gossamer Bio, Inc.
• BlackRock, Inc. beneficially owns an aggregate of 15,065,708 shares of Gossamer Bio, Inc. common stock.
• This ownership represents 6.5% of the total outstanding common stock of Gossamer Bio, Inc.
• BlackRock holds sole voting power over 14,859,077 shares and sole dispositive power over 15,065,708 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Investment Management, LLC, are identified as potentially owning 5% or more of the outstanding shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant passive stake by a major institutional investor, BlackRock, in Gossamer Bio. While not directly indicative of company performance, a large institutional holding can be viewed as a positive signal of confidence in the issuer's long-term prospects, assuming the investor is not seeking control.

Positives

• A major institutional investor like BlackRock holding a significant stake (6.5%) can be interpreted as a vote of confidence in Gossamer Bio, Inc.'s long-term prospects.
• BlackRock's certification of a passive investment strategy, not seeking to influence control, suggests stability in the ownership structure.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Gossamer Bio, Inc.'s future performance or BlackRock's future investment intentions beyond the passive nature of the current holding.

Management Comments

• The filing contains a certification from BlackRock, Inc. stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Gossamer Bio, Inc.

Industry Context

This filing reflects a significant institutional investment by BlackRock, a global asset manager, in Gossamer Bio, Inc. Such filings are common as large funds manage diverse portfolios. The specific industry context for Gossamer Bio, Inc. (e.g., biotechnology, pharmaceuticals) is not detailed in this ownership disclosure, but a 6.5% stake by a major institutional investor can signal perceived value within its sector.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure, indicating a passive stake above 5%. It does not provide performance metrics for Gossamer Bio, Inc. that would allow for a comparison to industry standards or specific comparable companies or projects. The ownership percentage itself is within typical ranges for institutional passive investments in publicly traded companies.

Stakeholder Impact

• Shareholders: May view BlackRock's significant stake as a positive signal of institutional confidence.
• Management: Awareness of a large, passive institutional holder in the company's stock.

Key Dates

Keywords

Gossamer Bio, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake